News

MicroPort® Endovastec™ Completes First Commercial Implantation of Minos™ in Ecuador and Hercules®-LP in Malaysia

Ecuador & Malaysia, 21 September, 2025 — Recently, MicroPort® Endovastec™ achieved two notable milestones in the aortic and peripheral vascular fields. The Minos™ Abdominal Aortic Stent Graft and Delivery System (Minos™) was successfully used in its first commercial case in Ecuador, while the Hercules™ Thoracic Stent Graft System with Low Profile Delivery System (Hercules™-LP) saw its first commercial implantation in Malaysia. These achievements further strengthen Endovastec™’s global presence, with products now available in over 45 markets.

First Minos™ Case in Ecuador

The inaugural Ecuador case was performed at Alfredo Paulson Hospital, led by Prof. Nicolas Blum’s team under the guidance of Prof. Alejandro Cuacci from Argentina.

The 66-year-old male patient presented with an acute large abdominal aortic aneurysm (diameter 74.1 mm) and a massive right iliac aneurysm (diameter 62 mm), with high rupture risk. Imaging revealed a tortuous, narrow access route. Based on preoperative planning, the surgical team selected the Minos™ system, completing the implantation smoothly with no endoleak. Postoperative imaging confirmed excellent graft morphology and improved vascular structure.

First Hercules™-LP Case in Malaysia

At the National Heart Institute (IJN) in Kuala Lumpur, Dr. Yew Pung Leong, Dr. Tan Kong Hean, and their team performed the first Malaysian case using the Hercules™-LP Straight Stent Graft.

The 62-year-old male patient was diagnosed with a ruptured thoracic aortic dissection requiring urgent TEVAR. The procedure achieved precise deployment, optimal anatomical conformity, and no endoleak.

Minos™ is now available in its fourth Latin American market after Brazil, Argentina, and Colombia. Hercules™-LP Straight Stent Graft becomes the third Endovastec™ product introduced in Malaysia, following Castor™ and Minos™. These milestones reflect progress in both regional coverage and product portfolio diversity.

About Minos™

Designed for endovascular repair of abdominal aortic aneurysms with a proximal aneurysm neck length of ≥15mm, Minos™ features:

  • First China-developed stent graft to reduce delivery system outer sheath to 14F, significantly reduces the requirements for vascular access.
  • Tri-modular design for in-body assembly, ideal for short/angulated necks and tortuous access.

Commercially available since 2019, it holds CE certification under both MDD and MDR and is in use in over 20 countries worldwide.

About Hercules™-LP

Engineered for straight aortic segments, Hercules™-LP offers:

  • A low-profile delivery system that can adapt to narrow and tortuous arteries.
  • A soft inner sheath within delivery system that protects the stent graft and simplifies crossing the arch.
  • A tip capture mechanism that ensures the accuracy and controllability of deployment.

Commercially available since 2015 and CE certified since 2020, it is in clinical use in more than 20 countries including the UK, Germany, Brazil, and Turkey.

About MicroPort® Endovastec™

Founded in 2012, MicroPort® Endovastec™ (Shanghai MicroPort Endovascular MedTech Group Co., Ltd.; SSE: 688016), an associated company of MicroPort® (MicroPort Scientific Corporation, HKEX: 00853), is a global medical device company focusing on R&D, manufacturing, and commercialization of aortic and peripheral vascular interventional devices. MicroPort® Endovastec™'s product portfolio includes thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, and drug-coated PTA balloon catheters. MicroPort® Endovastec™ breaks barriers and accelerates innovation to provide trustworthy and universal access to state-of-the-art solutions for prolonging and reshaping all lives, and to build a leading enterprise of emerging technologies in great vessel surgery and peripheral vascular medicine.

More information is available at: www.endovastec.com/en